Protalix Biotherapeutics, Inc. (PLX)
1.82
+0.07
(+4.00%)
USD |
NYAM |
Dec 10, 16:00
1.82
0.00 (0.00%)
After-Hours: 17:57
Protalix Biotherapeutics Cash from Financing (Quarterly): 0.00 for Sept. 30, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| GlucoTrack, Inc. | 2.994M |
| PAVmed, Inc. | -0.002M |
| AIM ImmunoTech, Inc. | 6.654M |
| Perspective Therapeutics, Inc. | 0.213M |
| Armata Pharmaceuticals, Inc. | 14.97M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.732M |
| Cash from Investing (Quarterly) | -0.504M |
| Free Cash Flow | -11.69M |
| Free Cash Flow Per Share (Quarterly) | -0.0523 |
| Free Cash Flow to Equity (Quarterly) | -7.058M |
| Free Cash Flow to Firm (Quarterly) | -4.041M |
| Free Cash Flow Yield | -8.17% |